RaySearch Laboratories: Interim report January 1 - March 31, 2024

Rhea-AI Summary

RaySearch Laboratories has released its interim report for Q1 2024. The company showed strong financial performance with order intake reaching SEK 238.5 M, net sales of SEK 257.2 M, and an operating profit of SEK 45.8 M. Profit after tax was SEK 36.7 M, and earnings per share stood at SEK 1.07. Significant events included RayStation's implementation in over 1,000 radiotherapy centers and the acquisition of DrugLog. Post-reporting period highlights include a collaboration agreement with C-RAD and RayCare being certified for interoperability with Varian TrueBeam.

Positive

• Order intake increased to SEK 238.5 M from 206.6 M.
• Net sales rose to SEK 257.2 M from 230.2 M.
• Operating profit grew to SEK 45.8 M from 23.7 M.
• Profit after tax doubled to SEK 36.7 M from 17.6 M.
• Earnings per share increased to SEK 1.07 from 0.51.
• Cash flow improved to SEK 87.9 M from 84.5 M.
• RayStation implemented in over 1,000 radiotherapy centers.
• Royal Marsden to implement ARTemis for online adaptive radiation therapy.
• Acquisition of DrugLog from Pharmacolog.
• QST in Chiba, Japan, selected RayStation.
• Raigmore Hospital in Scotland chose RayCare.
• RaySearch signed a collaboration agreement with C-RAD.
• RayCare certified for interoperability with Varian TrueBeam.

Negative

• Order backlog decreased to SEK 1,848.0 M from 1,903.3 M.

STOCKHOLM, May 17, 2024 /PRNewswire/ --

FIRST QUARTER (JANUARY - MARCH 2024)

• Oder intake SEK 238.5 M (206.6)
• Net sales SEK 257.2 M (230.2)
• Operating profit SEK 45.8 M (23.7)
• Profit after tax SEK 36.7 M (17.6)
• Earnings per share before/after dilution SEK 1.07 (0.51)
• Cash flow SEK 87.9 M (84.5)
• Order backlog SEK 1,848.0 M (1,903.3) MSEK at the end of the period

SIGNIFICANT EVENTS DURING THE FIRTS QUARTER

• RayStation in more than 1,000 radiotherapy centers worldwide.
• The Royal Marsden set to be the first center in the world to implement online adaptive radiation therapy utilizing ARTemis from RaySearch.
• RaySearch acquires the product DrugLog from Pharmacolog.
• World leading carbon ion center QST in Chiba, Japan, selects RayStation.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

• Raigmore Hospital in Scotland selects RayCare.
• RaySearch and C-RAD signed collaboration agreement.
• RayCare has been certified to be interoperable with Varian TrueBeam.

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch's interim report for January-March 2024 at a webcast to be held in English on Friday, May 17, 2024 at 10:00 a.m. CET.

Link to webcast: RaySearch Q1, 2024

You can also join the webcast by phone:
Sverige: +46 (0) 8 505 100 31
UK: +44 (0) 207 107 06 13
US: +1 (1) 631 570 56 13

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on May 17, 2024 at. 7:45 a.m. CET.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ) 
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/interim-report-january-1---march-31--2024,c3983281

The following files are available for download:

https://mb.cision.com/Main/1102/3983281/2803463.pdf

RaySearch Interim Report Q1 2024

 

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-january-1--march-31-2024-302148757.html

SOURCE RaySearch Laboratories

FAQ

What were RaySearch Laboratories' net sales for Q1 2024?

RaySearch Laboratories reported net sales of SEK 257.2 million for Q1 2024.

How much was RaySearch Laboratories' operating profit for Q1 2024?

The operating profit for RaySearch Laboratories in Q1 2024 was SEK 45.8 million.

What is RaySearch Laboratories' profit after tax for Q1 2024?

RaySearch Laboratories reported a profit after tax of SEK 36.7 million for Q1 2024.

What was RaySearch Laboratories' earnings per share for Q1 2024?

Earnings per share for RaySearch Laboratories in Q1 2024 were SEK 1.07.

How did RaySearch Laboratories' cash flow perform in Q1 2024?

RaySearch Laboratories reported a cash flow of SEK 87.9 million in Q1 2024.

What significant events occurred for RaySearch Laboratories in Q1 2024?

Significant events for RaySearch Laboratories in Q1 2024 included the implementation of RayStation in over 1,000 radiotherapy centers and the acquisition of DrugLog from Pharmacolog.

What collaborations were announced by RaySearch Laboratories after Q1 2024?

After Q1 2024, RaySearch Laboratories announced a collaboration agreement with C-RAD and that RayCare was certified to be interoperable with Varian TrueBeam.